Oculis Updates Share Capital For Its Existing At-The-Market Offering Program
Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the“Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each with a nominal value of CHF 0.01, ...